XML 63 R37.htm IDEA: XBRL DOCUMENT
v3.22.4

Research Collaboration and License Agreements - Additional Information (Details) | 1 Months Ended | 4 Months Ended | 12 Months Ended | 43 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Sep. 30, 2021 USD ($) $ / shares shares | Jul. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) $ / shares shares | Nov. 30, 2017 USD ($) Target | Dec. 31, 2015 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) shares | Dec. 31, 2020 USD ($) $ / shares shares | Dec. 31, 2018 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) | Jun. 30, 2019 USD ($)
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  | $ 0 |  |  | $ 10,700,000 | $ 12,500,000 | $ 0 |  | $ 10,700,000 |  |
Gross proceeds |  |  |  |  |  |  | 259,900,000 | 431,900,000 |  |  |  |
Collaboration contract asset and other assets |  |  |  |  |  | 10,800,000 | 12,500,000 |  |  | 10,800,000 |  |
Revenue adjustments arising from contract modifications |  |  |  |  |  | 700,000 | (800,000) | (400,000) |  |  |  |
Accounts receivable |  |  | $ 1,000,000.0 |  |  | 1,000,000.0 | $ 15,000,000.0 | $ 1,000,000.0 |  | 1,000,000.0 |  |
Common Shares |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Issuances of common stock, net (in shares) | shares |  |  | 6,571,428 |  |  |  | 3,500,000 | 6,600,000 |  |  |  |
Share price, issued and sold (in usd per share) | $ / shares |  |  | $ 70.00 |  |  |  |  | $ 70.00 |  |  |  |
Pfizer, Inc. |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payments received |  |  |  |  |  |  | $ 1,200,000 | $ 4,400,000 | $ 28,000,000 |  |  |
Pfizer, Inc. | Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  | $ 650,000,000 |  |  |  |  |  |  |  |  |  |
Collaboration agreement direct and incremental costs incurred |  |  |  |  |  | 12,900,000 |  |  |  |  |  |
Collaboration contract asset and other assets |  |  |  |  |  | 12,900,000 |  |  |  | 12,900,000 |  |
Pfizer, Inc. | Stock Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  | 650,000,000.0 |  |  |  |  |  |  |  |  |  |
Fair value of the shares sold |  | $ 85,400,000 |  |  |  |  |  |  |  |  |  |
Pfizer, Inc. | Stock Purchase Agreement | Common Shares |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Issuances of common stock, net (in shares) | shares | 3,457,815 |  |  |  |  |  |  |  |  |  |  |
Share price, issued and sold (in usd per share) | $ / shares | $ 101.22 |  |  |  |  |  |  |  |  |  |  |
Gross proceeds | $ 350,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Financial advisor fees | $ 4,600,000 |  |  |  |  |  |  |  |  |  |  |
Pfizer, Inc. | Development Milestone Payments | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 225,000,000 |  |  |  | 225,000,000 |  |
Pfizer, Inc. | Sales-based Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 1,000,000,000 |  |  |  | 1,000,000,000 |  |
Payments received |  |  |  |  |  | 0 |  |  |  |  |  |
Pfizer, Inc. | Sales-based Milestone Payments | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 550,000,000 |  |  |  | 550,000,000 |  |
Pfizer, Inc. | Option Payments | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 37,500,000 |  |  |  | 37,500,000 |  |
Pfizer, Inc. | Additional Target and Services |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  |  | 1,000,000 | 3,500,000 |  |  | 1,000,000 |  |
Pfizer, Inc. | Regulatory Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 400,000,000 |  |  |  | 400,000,000 |  |
Pfizer, Inc. | Regulatory Milestone Payments | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 1,400,000,000 |  |  |  | 1,400,000,000 |  |
Bayer A G |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  |  |  |  |  | $ 17,500,000
Bayer A G | Stock Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Fair value of the shares sold |  |  |  |  |  | 2,900,000 |  |  |  |  |  |
Additional consideration received |  |  |  |  |  | 2,900,000 |  |  |  |  |  |
Bayer A G | Research Funding Payments |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  | $ 3,000,000 |  |  | 3,000,000 | $ 3,000,000 | $ 3,000,000 |  | 3,000,000 |  |
Payments received |  |  |  |  |  |  |  |  |  | 10,500,000 |  |
Bayer A G | Research Funding Payments | Scenario Forecast |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  |  |  |  | $ 12,000,000 |
Bayer A G | Development Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payments received |  |  |  |  |  | 0 |  |  |  |  |  |
Bayer A G | Development Milestone Payments | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  |  |  |  |  | 197,500,000
Bayer A G | Sales-based Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payments received |  |  |  |  |  | 0 |  |  |  |  |  |
Bayer A G | Sales-based Milestone Payments | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  |  |  |  |  | $ 490,000,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payments received |  |  |  | $ 34,500,000 | $ 11,000,000 |  |  |  |  |  |  |
Number of designated targets | Target |  |  |  | 10 |  |  |  |  |  |  |  |
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payments received |  |  |  |  |  | 0 |  |  |  |  |  |
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 44,000,000 |  |  |  | 44,000,000 |  |
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Option Payments | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 27,500,000 |  |  |  | 27,500,000 |  |
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 52,500,000 |  |  |  | 52,500,000 |  |
Payments received |  |  |  |  |  | 0 |  |  |  |  |  |
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  | 60,000,000 |  |  |  | $ 60,000,000 |  |
Payments received |  |  |  |  |  | $ 0 |  |  |  |  |  |

X
- Definition Collaboration Contract Asset And Other Assets + References No definition available. + Details
Name: | arvn_CollaborationContractAssetAndOtherAssets
Namespace Prefix: | arvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Direct And Incremental Costs Incurred To Obtain The Contract + References No definition available. + Details
Name: | arvn_DirectAndIncrementalCostsIncurredToObtainTheContract
Namespace Prefix: | arvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of maximum designated targets. + References No definition available. + Details
Name: | arvn_NumberOfMaximumDesignatedTargets
Namespace Prefix: | arvn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research collaboration and license agreements. + References No definition available. + Details
Name: | arvn_ResearchCollaborationAndLicenseAgreementsLineItems
Namespace Prefix: | arvn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sale of stock, fair value of shares sold. + References No definition available. + Details
Name: | arvn_SaleOfStockFairValueOfSharesSold
Namespace Prefix: | arvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForBrokerageFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedPerTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_AdditionalTargetAndServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=arvn_BayerAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |